arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

JUPITER NEUROSCIENCES, INC.

JUNS
$2.93 ▼ -0.12 (-3.93%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
19 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Neutral Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, JUPITER NEUROSCIENCES, INC. shows solid but mixed fundamentals, with Return on Invested Capital holding up well. Watch FCF / Net Income against typical quality thresholds. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $1.6M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 592.1%
FCF / Share $-4.12
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$24.25K
↑ +30.0%
Net Income Profit after all expenses
$-2.06M
↓ -34.9%
FCF / Share Free cash flow per share
$-4.12
↓ -10032.7%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • Return on Invested CapitalReturn on Invested Capital of 384.2% is excellent on an absolute basis (target > 10%)
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.63x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 4 years · 15 quarters